Tumor Liquid Biopsies

  • Florence Schaffner
  • Jean-Louis Merlin
  • Nikolas von Bubnoff

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 215)

Table of contents

  1. Front Matter
    Pages i-vi
  2. Circulating Tumor Cells (CTC)

    1. Front Matter
      Pages 1-1
    2. Tilman Todenhöfer, Klaus Pantel, Arnulf Stenzl, Stefan Werner
      Pages 3-24
    3. Mert Boya, Chia-Heng Chu, Ruxiu Liu, Tevhide Ozkaya-Ahmadov, Ali Fatih Sarioglu
      Pages 25-55
    4. Michael Paul Kolinsky, Nikolas Stoecklein, Maryou Lambros, Veronica Gil, Daniel Nava Rodrigues, Suzanne Carreira et al.
      Pages 57-76
    5. Mark Kalinich, Tanya T. Kwan, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran
      Pages 77-88
    6. Kevin Keomanee-Dizon, Stephanie N. Shishido, Peter Kuhn
      Pages 89-104
    7. Francesca Chemi, Sumitra Mohan, Ged Brady
      Pages 105-125
    8. Diana H. Liang, Carolyn Hall, Anthony Lucci
      Pages 127-145
    9. Erin F. Cobain, Costanza Paoletti, Jeffrey B. Smerage, Daniel F. Hayes
      Pages 147-160
  3. Circulating Tumor DNA (ctDNA)

  4. Circulating Tumor RNA, Exosomes

    1. Front Matter
      Pages 275-275
    2. Gitte Brinch Andersen, Jörg Tost
      Pages 277-298
    3. Sabrina Müller, Florian Janke, Steffen Dietz, Holger Sültmann
      Pages 299-318
  5. Bioinformatics

    1. Front Matter
      Pages 345-345
    2. Francesco Marass, Francesc Castro-Giner, Barbara Maria Szczerba, Katharina Jahn, Jack Kuipers, Nicola Aceto et al.
      Pages 347-368

About this book


This book is a comprehensive guide to the techniques, clinical applications, and benefits of the different forms of liquid biopsy employed in patients with a variety of tumor types, including lung, breast and colorectal cancer. Offering detailed explanations, it discusses the how changes in tumors can be tracked using these cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics. The use of such advanced technologies is enabling us to tackle questions and problems in a way that was not possible just a few years ago. We now have at our disposal an effective means of overcoming the problem of intratumor heterogeneity, which has limited the value of conventional biopsy approaches. As a consequence, oncology practice is about to change radically, toward truly personalized precision medicine. This book provides both clinicians and researchers with a thorough and up-to-date overview of progress in the field.


Liquid Biopsy Circulating Biomarkers Precision Medicine Circulating Tumor cells Circulatin Nucleic Acid Personalized Medicine

Editors and affiliations

  • Florence Schaffner
    • 1
  • Jean-Louis Merlin
    • 2
  • Nikolas von Bubnoff
    • 3
  1. 1.Cancéropôle Est StrasbourgFrance
  2. 2.Institut de Cancérologie de LorraineCNRS UMR7039 CRAN, Université de LorraineVandoeuvre-lès-NancyFrance
  3. 3.Department of Hematology and Oncology, Medical CenterUniversity of Schleswig-HolsteinLübeckGermany

Bibliographic information

  • DOI
  • Copyright Information Springer Nature Switzerland AG 2020
  • Publisher Name Springer, Cham
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-3-030-26438-3
  • Online ISBN 978-3-030-26439-0
  • Series Print ISSN 0080-0015
  • Series Online ISSN 2197-6767
  • Buy this book on publisher's site